Search research articles
Contact Us
Filters
Showing results (331-340 of 366) with videos related to
Page
of 37
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity
Gerald P Linette, Dongsheng Zhang, F Stephen Hodi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 17, 2003
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
F Stephen Hodi, Martin C Mihm, Robert J Soiffer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2006
Innovations and challenges in melanoma: summary statement from the first Cambridge conference
Michael B Atkins, David E Elder, Richard Essner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2009
Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience
Lilyana Angelov, Nancy D Doolittle, Dale F Kraemer, et al.
British Journal of Cancer
|
October 8, 2014
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
I Brana, R Berger, T Golan, et al.
Cancer Research
|
November 16, 2014
Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer
Evanthia Galanis, Pamela J Atherton, Matthew J Maurer, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 22, 2008
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F Stephen Hodi, Marcus Butler, Darryl A Oble, et al.
Cancer Journal (Sudbury, Mass.)
|
July 6, 2000
Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma
E Jonasch, U N Kumar, G P Linette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Roisin M Connolly, Eric Laille, Ulka Vaishampayan, et al.
Journal of the National Cancer Institute
|
May 23, 2018
Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy
Cheyne Kurokawa, Ianko D Iankov, S Keith Anderson, et al.
Page
of 37
Search research articles
Search
Showing results (331-340 of 366) with videos related to
Sort By:
Page
of 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity
Gerald P Linette, Dongsheng Zhang, F Stephen Hodi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 17, 2003
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
F Stephen Hodi, Martin C Mihm, Robert J Soiffer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2006
Innovations and challenges in melanoma: summary statement from the first Cambridge conference
Michael B Atkins, David E Elder, Richard Essner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2009
Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience
Lilyana Angelov, Nancy D Doolittle, Dale F Kraemer, et al.
British Journal of Cancer
|
October 8, 2014
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
I Brana, R Berger, T Golan, et al.
Cancer Research
|
November 16, 2014
Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer
Evanthia Galanis, Pamela J Atherton, Matthew J Maurer, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 22, 2008
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F Stephen Hodi, Marcus Butler, Darryl A Oble, et al.
Cancer Journal (Sudbury, Mass.)
|
July 6, 2000
Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma
E Jonasch, U N Kumar, G P Linette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Roisin M Connolly, Eric Laille, Ulka Vaishampayan, et al.
Journal of the National Cancer Institute
|
May 23, 2018
Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy
Cheyne Kurokawa, Ianko D Iankov, S Keith Anderson, et al.
Page
of 37